What is this study about?
Sonlicromanol (KH-176) research has entered a new phase with a Phase 2b clinical trial now open for recruitment.
The aim of the study is to further assess efficacy of Sonlicromanol in improving cognitive function in individuals with symptomatic m. 3243A>G mitochondrial disease.
Who can take part?
The study team is looking to recruit around 27 participants over 18 years old with m.3243 A>G mutation and the following symptoms: headaches, migraine, fatigue, exercise intolerance, hearing loss, epilepsy, developmental delay, ataxia, diabetes, gastrointestinal complaints.
What's involved in taking part?
Each participant would have to come to the study site for a screening visit to ensure they meet inclusion criteria and do not meet exclusion criteria. The study will last for 6 months in total, during this time participants will experience 3 treatment periods where they will be taking a higher dose of medication (100mg), lower dose (50mg) and a placebo. Each treatment period will last for about a month with a washout period in between.
Where is the study taking place?
The study is taking place at three Centres across Europe in Newcastle upon Tyne (UK), Munich (Germany) and Nijmegen (Netherlands).
How do I find out more?
If you are interested to know more about the study please contact Dr Oksana Pogoryelova:
Email: [email protected]
Tel: 0191 208 3008
